Clinical trial NCT06776081: Adipocyte-Derived Extracellular Vesicles, Weight Loss, and Endothelial Function
Official title: Adipocyte-Derived Extracellular Vesicles; Novel Biomarker and Mediator of Obesity-Related Endothelial Dysfunction
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Obesity
Weight Loss
Keywords: Obesity
Weight Loss
Lead sponsor: University of Colorado, Boulder
Sponsor class: OTHER
First posted: 2025-01-15
Enrollment: 84
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: Changes in adipose tissue biology are now recognized as a key factor underlying the increased risk of metabolic and cardiovascular disease with obesity. Clinical interest in adipocyte-derived extracellular vesicles (Ad-EVs) has intensified due to their potential as circulating biomarkers of adipose tissue health and systemic messengers, regulators and mediators of cardiometabolic health and disease with obesity.

The investigators hypothesize that elevated Ad-EVs in adults with obesity will be negatively associated with endothelium-dependent vasodilation. Furthermore, the investigators hypothesize that in adults with obesity, intentional weight loss-induced reduction in circulating Ad-EVs is associated with greater endothelium-dependent vasodilation.


Eligibility criteria: Inclusion criteria:

* Age ≥40 years
* BMI \<25 kg/m2 and BMI \>25 kg/m2 for Phase 1 and BMI \>25 kg/m2 for Phase 2. Rationale for defining obesity as BMI \>25 kg/m2

Exclusion criteria:

* Current smoker
* Chronic overt medical condition (e.g., evidence of coronary artery disease on resting ECG, any history of myocardial infarction or stroke, or cancer, diabetes based on fasting blood glucose concentration)
* Alcohol abuse or dependence defined as more than 14 standard drinks/week and no more than 4 standard drinks/day for men and 7 standard drinks/week and 3 standard drinks/day for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wines, 1 ½ ounces of 80-proof distilled spirits) reported during the medical history/physical exam
* Stage III hypertension (systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg)
* Regular vigorous aerobic/endurance exercise (\>3 bouts/week, \>30 minutes/bout at a workload \>6 METS)
* Women who are pregnant or breastfeeding
* History of anaphylaxis to betadine, lidocaine, iodine
* Raynaud's disease
* History of clotting disorders
* Anyone taking blood thinners and clotting medications
* Anyone taking statin medication
* Planned pregnancy in coming 4-6 months

Primary outcomes:
measure: Phase 1: Circulating adipocyte-derived extracellular vesicles (Ad-EVs)
timeFrame: Circulating Ad-EVs will measured during Phase 1 visit 2 which is ~2 weeks from their respective start date.
measure: Phase 2: Circulating adipocyte-derived extracellular vesicles (Ad-EVs)
timeFrame: Circulating Ad-EVs will be measured during Phase 2 visit 15 which is ~17 weeks from their respective start date.
measure: Phase 1: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh)
timeFrame: FBF response to ACh will be measured during Phase 1 and the participant's visit 2 which is ~ 2 weeks from their respective start date.
measure: Phase 2: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh)
timeFrame: FBF response to ACh will be measured during Phase 2 and the participant's visit 15 which is ~17 weeks from their respective start date.
measure: Phase 1: Forearm Blood Flow (FBF) Response to Sodium Nitroprusside (NTP)
timeFrame: FBF response to NTP will be measured during Phase 1 and the participant's visit 2 which is ~ 2 weeks from their respective start date.
measure: Phase 2: Forearm Blood Flow (FBF) Response to Sodium Nitroprusside (NTP)
timeFrame: FBF response to NTP will be measured during Phase 2 and the participant's visit 15 which is ~17 weeks from their respective start date.
Secondary outcomes:
Other outcomes:
Locations:
city: Boulder
country: United States
facility: University of Colorado Boulder Clinical and Translational Research Center (CTRC)
state: Colorado
Study officials:
affiliation: University of Colorado, Boulder
name: Christopher DeSouza, PhD
role: PRINCIPAL_INVESTIGATOR
References: